Physician profile
Scott D Gardner
NPI 1457613655
$4,680.90
in general payments reported to CMS, 2019-2025
22 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $385 · 2021: $622 · 2022: $889 · 2023: $861 · 2024: $575 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,001.68 | 2019-2025 | Cequa |
| Alcon Vision LLC | $449.81 | 2019-2025 | Rocklatan, Lensx, Rhopressa |
| Allergan, INC. | $438.47 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $382.89 | 2019-2023 | |
| Oyster Point Pharma, INC. | $338.90 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $290.71 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $255.53 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $250.77 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Kala Pharmaceuticals, INC. | $242.89 | 2019-2021 | |
| Abbvie INC. | $188.12 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $149.78 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.79 | 2019-2021 | |
| New World Medical,INC. | $99.94 | 2022-2025 | Clearpath, Kahook Dual Blade, Via360 |
| Akorn Operating Company LLC | $96.74 | 2021 | |
| Dompe US, INC. | $85.55 | 2024-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $78.81 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $55.57 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $40.08 | 2019-2020 | |
| Omeros Corporation | $39.84 | 2019-2020 | |
| Sight Sciences, INC. | $37.27 | 2019-2021 | |
| Rxsight INC | $18.01 | 2022 | |
| Horizon Therapeutics Plc | $17.75 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.